These clauses include failing to document and publicly disclose annually certain payments made directly or indirectly to health professionals, other relevant decision-makers and healthcare organisations, failing to make publicly available a list of patient organisations which it supports, and failing to make disclosures annually in respect of each calendar year in the first six months after the end of the calendar year in which the payments were made.
It noted that the company “had been the subject of several cases in relation to the failure to appropriately disclose transfers of value,” adding that “additional sanctions had been imposed and that Novo Nordisk was already the subject of the audit process at the request of the code of practice appeal board”.
Following an “in-depth investigation”, the complainants claimed Novo Nordisk allegedly failed to report, inaccurately reported, and misreported payments to healthcare organisations and patient organisations between 2015 and 2022.
A Novo Nordisk spokesman said: “Novo Nordisk is dedicated to working transparently and ethically, taking the reporting of these historical transfers of value extremely seriously.
Novo Nordisk breached clauses under the Association of the British Pharmaceutical Industry (ABPI) code of practice, according to the Prescription Medicines Code Of Practice Authority (PMCPA).
.jpeg?trim=312,0,313,0&quality=75&auto=webp&width=1000)
